Bristol Myers Squibb Reports Phase 3 CheckMate-017 Results for Opdivo in Squamous NSCLC

Bristol Myers Squibb today announced results from the Phase 3 CheckMate-017 trial evaluating Opdivo (nivolumab) versus docetaxel in patients with previously treated advanced squamous non-small cell lung cancer. The trial met its primary endpoint, demonstrating a significant improvement in overall survival with Opdivo. These results led to FDA approval of Opdivo for squamous NSCLC.